Breaking News Instant updates and real-time market news.

AMGN

Amgen

$144.07

-1.93 (-1.32%)

, CYTK

Cytokinetics

$12.00

-0.35 (-2.83%)

18:34
11/30/16
11/30
18:34
11/30/16
18:34

Amgen, Cytokinetics say COSMIC-HF trial met primary pharmacokinetic objective

Amgen (AMGN) and Cytokinetics (CYTK) announced The Lancet published results from a Phase 2 clinical trial evaluating omecamtiv mecarbil in patients with chronic heart failure. The COSMIC-HF trial met its primary pharmacokinetic objective and showed statistically significant improvements in all pre-specified secondary measures of cardiac function in the treatment group receiving pharmacokinetic-based dose titration. The results were initially presented as a Late-Breaking Clinical Trial at the American Heart Association Scientific Sessions 2015. The trial, which evaluated 448 patients with chronic heart failure and left ventricular systolic dysfunction, showed that dose titration controlled patient exposure to omecamtiv mecarbil. Patients were randomized 1:1:1 to receive either placebo or treatment with omecamtiv mecarbil dosed as 25 mg twice daily or 25 mg with dose escalation to 50 mg twice daily, depending on plasma concentrations of omecamtiv mecarbil after two weeks of treatment. The pharmacokinetic-based dose titration strategy was designed to maintain patient exposure to omecamtiv mecarbil in the targeted plasma concentration range. Approximately 53% of patients in the dose titration group were escalated to a dose of 50 mg twice daily. Adverse events, including serious AEs, in patients on omecamtiv mecarbil were comparable to placebo. The incidence of adjudicated deaths, myocardial infarction and unstable angina was similar. Other cardiac AEs were generally balanced between placebo and active treatment groups. In patients receiving omecamtiv mecarbil compared to placebo, cardiac troponin increased by 0.001 ng/mL and 0.006 ng/mL in the 25 mg twice daily group and dose titration group, respectively. Events of increased troponin were independently adjudicated and none were adjudicated as an episode of myocardial ischemia or infarction.

AMGN

Amgen

$144.07

-1.93 (-1.32%)

CYTK

Cytokinetics

$12.00

-0.35 (-2.83%)

  • 30

    Nov

  • 07

    Dec

  • 19

    Jul

AMGN Amgen
$144.07

-1.93 (-1.32%)

11/07/16
MZHO
11/07/16
INITIATION
Target $164
MZHO
Buy
Amgen initiated with a Buy at Mizuho
Mizuho analyst Salim Syed initiated Amgen with a Buy rating and a $164 price target.
11/08/16
ARGS
11/08/16
NO CHANGE
ARGS
Amgen weakness creates buying opportunity, says Argus
After Amgen's stock sunk 10% following its Q3 results, Argus says that the decline was triggered by "news that pricing power for Enbrel would be limited in 2017." However, the firm says that the company's growth outlook is "solid," while it has launched "promising new drugs." The firm keeps a Buy rating on the stock.
11/08/16
11/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
CYTK Cytokinetics
$12.00

-0.35 (-2.83%)

12/16/15
PIPR
12/16/15
NO CHANGE
Target $24
PIPR
Overweight
Cytokinetics price target raised to $24 from $17 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised its price target for Cytokinetics to $24 citing greater conviction in the company's pipeline assets ahead of its "busy" 2016. Piper views Cytokinetics as the leader in muscle-biology and reiterates an Overweight rating on the name.
06/21/16
FBRC
06/21/16
NO CHANGE
Target $24
FBRC
Outperform
FBR views Cytokinetics as attractive despite 36% rally
Even with shares up 36% since added to his firm's Alpha Generator list in March, FBR Capital analyst Vernon Bernardino still views shares of Cytokinetics (CYTK) as attractive for an initial investment. The analyst believes partner Amgen (AMGN) will exercise its option and advance omecamtiv mecarbil into Phase III testing in heart failure. Bernardino keeps an Outperform rating on the shares with a $24 price target.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.57

0.03 (0.05%)

19:34
02/22/17
02/22
19:34
02/22/17
19:34
Hot Stocks
Market researcher: Starbucks consumer perception dips after refugee hiring news »

Market researcher YouGov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

LB

Labarge

$58.13

0.43 (0.75%)

19:33
02/22/17
02/22
19:33
02/22/17
19:33
Hot Stocks
L Brands sees Q1 comps down high-single to low-double digits »

Sees Q1 Go-Forwards comps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

19:32
02/22/17
02/22
19:32
02/22/17
19:32
Hot Stocks
L Brands sees FY17 comps down low-single digits »

Sees FY17 Go-Forward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

F

Ford

$12.67

-0.02 (-0.16%)

19:30
02/22/17
02/22
19:30
02/22/17
19:30
Conference/Events
Ford to host sales conference call »

Ford U.S. Sales Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

GTLS

Chart Industries

$38.51

-1.21 (-3.05%)

19:27
02/22/17
02/22
19:27
02/22/17
19:27
Hot Stocks
Chart Industries CEO Samuel Thomas named executive chairman »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$273.51

-3.88 (-1.40%)

19:24
02/22/17
02/22
19:24
02/22/17
19:24
Periodicals
SolarCity leased with risky homeowners, has ties to foreclosure cases, NYT says »

In "dozens of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

PRU

Prudential

$110.50

-0.72 (-0.65%)

, WFC

Wells Fargo

$58.36

0.11 (0.19%)

19:16
02/22/17
02/22
19:16
02/22/17
19:16
Hot Stocks
Prudential says could seek compensation from Wells Fargo over MyTerm products »

Prudential (PRU) stated…

PRU

Prudential

$110.50

-0.72 (-0.65%)

WFC

Wells Fargo

$58.36

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 13

    Apr

  • 06

    Jun

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

PSA

Public Storage

$226.24

-1.49 (-0.65%)

19:15
02/22/17
02/22
19:15
02/22/17
19:15
Earnings
Public Storage reports Q4 core FFO $2.65, consensus $1.89 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

19:10
02/22/17
02/22
19:10
02/22/17
19:10
Periodicals
Credit Suisse probed for potentially aiding tax evasion, WSJ says »

Less than three years…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

LZB

La-Z-Boy

$28.40

-1.05 (-3.57%)

19:09
02/22/17
02/22
19:09
02/22/17
19:09
Downgrade
La-Z-Boy rating change  »

La-Z-Boy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CLD

Cloud Peak

$5.68

-0.19 (-3.24%)

19:06
02/22/17
02/22
19:06
02/22/17
19:06
Syndicate
Cloud Peak 13.5M share Spot Secondary priced at $5.10 »

Credit Suisse, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SNAP

Snap Inc

18:47
02/22/17
02/22
18:47
02/22/17
18:47
Periodicals
Snap Inc nears $200M ad deal, NY Post says »

Snap Inc is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SBLK

Star Bulk Carriers

$9.59

0.29 (3.12%)

18:40
02/22/17
02/22
18:40
02/22/17
18:40
Earnings
Star Bulk Carriers reports Q4 EPS (29c), consensus (28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 22

    Mar

C

Citi

$60.62

0.07 (0.12%)

18:35
02/22/17
02/22
18:35
02/22/17
18:35
Periodicals
Citi forms regulatory affairs team in D.C., Bloomberg says »

Citi is forming a global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:34
02/22/17
02/22
18:34
02/22/17
18:34
Earnings
PRA Health sees FY17 EPS $3.08-$3.18, consensus $2.96 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

, ATH

Athene Holding

$51.45

0.38 (0.74%)

18:32
02/22/17
02/22
18:32
02/22/17
18:32
Periodicals
Fidelity & Guaranty Life revives sale process, Insurance Insider says »

Fidelity & Guaranty…

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

ATH

Athene Holding

$51.45

0.38 (0.74%)

APO

Apollo Global

$22.25

0.05 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:31
02/22/17
02/22
18:31
02/22/17
18:31
Earnings
PRA Health sees Q1 EPS 57c-62c, consensus 67c »

Sees Q1 service revenues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NBR

Nabors Industries

$15.44

0.01 (0.06%)

18:30
02/22/17
02/22
18:30
02/22/17
18:30
Earnings
Nabors Industries reports Q4 EPS ($1.17) with items »

Q4 EPS includes 87c in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

18:28
02/22/17
02/22
18:28
02/22/17
18:28
Earnings
AxoGen reiterates FY17 revenue growth view of at least 40% »

Management reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

  • 21

    Mar

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

18:26
02/22/17
02/22
18:26
02/22/17
18:26
Earnings
AxoGen reports Q4 EPS (10c), consensus (9c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

  • 21

    Mar

GEN

Genesis Healthcare

$3.83

-0.05 (-1.29%)

18:26
02/22/17
02/22
18:26
02/22/17
18:26
Earnings
Genesis Healthcare sees FY17 revenue $5.4B-$5.6B, consensus $5.64B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

URRE

Uranium Resources

$1.91

-0.06 (-3.05%)

18:25
02/22/17
02/22
18:25
02/22/17
18:25
Hot Stocks
Uranium Resources reports favorable lithium concentrations at Columbus Basin »

Uranium Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GEN

Genesis Healthcare

$3.83

-0.05 (-1.29%)

18:24
02/22/17
02/22
18:24
02/22/17
18:24
Earnings
Genesis Healthcare reports Q4 revenue $1.4B, consensus $1.4B »

Reports Q4 net income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

MCRI

Monarch Casino

$23.98

-0.22 (-0.91%)

18:22
02/22/17
02/22
18:22
02/22/17
18:22
Earnings
Monarch Casino reports Q4 EPS 36c, consensus 33c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBMX

CombiMatrix

$4.10

-0.1 (-2.38%)

, UCTT

Ultra Clean

$12.58

0.2 (1.62%)

18:22
02/22/17
02/22
18:22
02/22/17
18:22
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

CBMX

CombiMatrix

$4.10

-0.1 (-2.38%)

UCTT

Ultra Clean

$12.58

0.2 (1.62%)

SQ

Square

$15.04

0.41 (2.80%)

CTRP

Ctrip.com

$47.59

0.53 (1.13%)

TSLA

Tesla

$273.51

-3.88 (-1.40%)

BLCM

Bellicum Pharmaceuticals

$12.79

-0.6 (-4.48%)

LB

Labarge

$58.13

0.43 (0.75%)

TSRA

Tessera

$44.65

-0.2 (-0.45%)

ARRS

ARRIS

$30.70

0.75 (2.50%)

JACK

Jack in the Box

$103.60

-3.77 (-3.51%)

SAM

Boston Beer

$166.85

-1.9 (-1.13%)

ELGX

Endologix

$6.53

0.04 (0.62%)

CSGP

CoStar Group

$210.02

-1.35 (-0.64%)

FMI

Foundation Medicine

$23.85

-0.6 (-2.45%)

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

CLD

Cloud Peak

$5.68

-0.19 (-3.24%)

NGD

New Gold

$3.04

-0.08 (-2.56%)

NVDA

NVIDIA

$110.76

-0.31 (-0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 14

    Mar

  • 16

    Mar

  • 16

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 22

    Mar

  • 23

    Mar

  • 23

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 23

    Feb

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.